Zobrazeno 1 - 10
of 22
pro vyhledávání: '"L. A Zvenigorodskaya"'
Publikováno v:
КардиоСоматика, Vol 1, Iss 1, Pp 38-45 (2010)
Dyslipidemia is currently accepted to be one of the major risk factor for cardiovascular diseases and atherosclerosis. There is no question that the liver plays an important role in the development of atherogenic dyslipidemia and it is simultaneously
Externí odkaz:
https://doaj.org/article/582aaedddfe4428eb79fdd5e273fd80b
Autor:
L. A. Zvenigorodskaya
Publikováno v:
Медицинский совет, Vol 0, Iss 3, Pp 49-53 (2018)
The incidence of non-alcoholic fatty liver disease (NAFLD) in the Russian Federation is increasing rapidly in proportion to the increase in the number of patients with obesity, hypertension, dyslipidemia, diabetes mellitus, et al. The incipient and o
Externí odkaz:
https://doaj.org/article/9bfbff01f59f4a51a29a7f00842676eb
Publikováno v:
Медицинский совет, Vol 0, Iss 20, Pp 20-25 (2018)
According to the World Health Organization estimates, non-alcoholic fatty liver disease (NAFLD) will be ranked number one in the liver diseases pattern by 2020. Liver transplantation in patients with cirrhosis as the outcome of NAFLD currently ranks
Externí odkaz:
https://doaj.org/article/b2b500316c0d416d8e5c867573c9bf6e
Autor:
N. M. Achmegdanov, S. A. Butrusova, I. I. Dedov, L. A. Zvenigorodskaya, O. A. Kislyak, O. A. Koshelskaya, I. V. Kuznecova, V. V. Kuharchuk, A. Yu. Litvin, I. V. Medvedeva, A. M. Mkrtumyan, V. B. Mychka, D. V. Nebieridze, S. V. Nedogoda, R. G. Oganov, M. Yu. Ogarkov, N. B. Perepech, V. I. Podzolkov, V. P. Smetnik, A. V. Susekov, V. N. Titov, T. V. Tyurina, A. N. Fursov, V. N. Hirmanov, I. E. Chazova, I. I. Chukaeva, M. V. Shestakova, A. T. Shubina
Publikováno v:
Рациональная фармакотерапия в кардиологии, Vol 6, Iss 4, Pp 599-606 (2016)
Russian Experts’ Consensus on Metabolic Syndrome Problem in the Russian Federation: Defenition, Diagnosis Criteria, Primary Prevention and Treatment.
Externí odkaz:
https://doaj.org/article/b0d7c7c4bf1f43db936192ee633a9513
Publikováno v:
Effective Pharmacotherapy. 16:8-14
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::b0cedf0b04401a95b562cf147d7d6734
https://doi.org/10.33978/2307-3586-2020-16-12-8-14
https://doi.org/10.33978/2307-3586-2020-16-12-8-14
Autor:
N M Akhmedzhanov, S A Butrova, I I Dedov, L A Zvenigorodskaya, O A Kislyak, O A Koshel'skaya, I V Kuznetsova, V V Kukharchuk, A Yu Litvin, I V Medvedeva, A M Mkrtumyan, V B Mychka, D V Nebieridze, S V Nedogoda, V G Oganov, M Yu Ogarkov, N B Perepech, V I Podzolkov, V P Smetnik, A V Susekov, V N Titov, T V Tyurina, A N Fursov, V N Khirmanov, I E Chazova, I I Chukaeva, M V Shestakova, A T Shubina
Publikováno v:
Гинекология, Vol 12, Iss 3, Pp 25-30 (2010)
Externí odkaz:
https://doaj.org/article/1baecc92e6e1443695bae5a0ce87c99e
Publikováno v:
Кардиоваскулярная терапия и профилактика, Vol 8, Iss 3, Pp 69-77 (2009)
Aim. To study clinical, functional, morphological and pharmacological features of hepatic pathology in patients with non-alcohol hepatic steatosis (NAHS), combined with atherogenic dyslipidemia (ADL) and/or insulin resistance (IR).Material and method
Externí odkaz:
https://doaj.org/article/7ce827398b03452fb06b3cc0922ba14c
Publikováno v:
Experimental and Clinical Gastroenterology. 163:81-88
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::3dbd4c64822057e26cc3d34cad4002e7
https://doi.org/10.31146/1682-8658-ecg-163-3-81-88
https://doi.org/10.31146/1682-8658-ecg-163-3-81-88
Publikováno v:
Eksperimental'naia i klinicheskaia gastroenterologiia = Experimentalclinical gastroenterology. (11)
Bile acids regulate glucose and lipid metabolism. Aim -determination of total serum bile acids in patients with NAFLD and in combination with type 2 diabetes. To determine the inflammatory markers (nitric oxide, endotoxin, phospholipase A2, malondial
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::c82a6840074855b2febb3832830ae06c
https://pubmed.ncbi.nlm.nih.gov/29889442
https://pubmed.ncbi.nlm.nih.gov/29889442
Autor:
L B, Lazebnik, V G, Radchenko, E V, Golovanova, L A, Zvenigorodskaya, Yu V, Konev, P V, Seliverstov, S I, Sitkin, E I, Tkachenko, E K, Aylamazayn, N N, Vlasov, E A, Kornienko, V P, Novikova, L P, Horoshinina, N V, Zhestkova, L S, Oreshko, O P, Dudanova, V P, Dobrica, L V, Turyeva, O V, Tirikova, N M, Kozlova, S M, Eliseev, R R, Gumerov, E V, Vencak
Publikováno v:
Eksperimental'naia i klinicheskaia gastroenterologiia = Experimentalclinical gastroenterology. (7)
According to the World Health Organization, it is recorded steady growth of the number of chronic liver diseases, including nonalcoholic fatty liver disease (NAFLD), in recent years. As an independent nosological entity, NAFLD is one of the risk fact
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::fb3d994ab85c2a3027ef864939035bb4
https://pubmed.ncbi.nlm.nih.gov/26817127
https://pubmed.ncbi.nlm.nih.gov/26817127